Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]